Suppr超能文献

巨细胞病毒供体血清学阳性对心脏移植后的生存产生负面影响。

Cytomegalovirus Donor Seropositivity Negatively Affects Survival After Heart Transplantation.

作者信息

Heim Christian, Müller Philipp P, Tandler René, Cherikh Wida S, Toll Alice E, Stehlik Josef, Weyand Michael, Khush Kiran K, Ensminger Stephan M

机构信息

Department of Cardiac Surgery, University of Erlangen-Nuremberg, Erlangen, Germany.

United Network for Organ Sharing, Richmond, VA.

出版信息

Transplantation. 2022 Jun 1;106(6):1243-1252. doi: 10.1097/TP.0000000000003961. Epub 2022 Sep 23.

Abstract

BACKGROUND

Prior studies have shown that cytomegalovirus (CMV) infection is a risk factor for the development of cardiac allograft vasculopathy (CAV) and is associated with reduced long-term survival after heart transplantation (HTx). The aim of this International Society for Heart and Lung Transplantation Transplant Registry study was to compare posttransplant survival in different CMV donor:recipient serologic combinations.

METHODS

We performed a retrospective cohort study, using the International Society for Heart and Lung Transplantation Thoracic Transplant Registry, on 15 885 adult primary heart transplant recipients with known CMV serologic status between July 2004 and June 2014. Posttransplant survival and risk of developing CAV were compared across 4 groups: CMV-seronegative recipients (R-) receiving CMV-positive grafts (D+), intermediate-risk patients (D+R+ and D-R+), and low-risk patients (D-R-).

RESULTS

Baseline characteristics (donor/recipient age, body mass index, recipient serum creatinine, blood group, donor cause of death, recipient diagnosis, and ischemic time) were mostly balanced between the groups. Kaplan-Meier survival analyses over a follow-up of 10 y revealed significantly worse survival for both D+ groups as compared to the CMV low-risk group (D+R+: 56.61% [95% confidence interval, 53.94-59.41] versus D-R-: 63.09% [59.74-66.64] P < 0.01 and D+R-: 57.69% [56.03-59.39] versus D-R-; P < 0.001), whereas recipient seropositivity alone was not associated with reduced survival (D-R+ versus D-R-P = 0.178). The risk of developing CAV after HTx was not significantly increased in D+ as compared to D- groups.

CONCLUSIONS

In a large contemporary cohort, CMV status at the time of HTx was not associated with CAV development. However, there was a significant association between donor CMV seropositivity and reduced short- and long-term survival after HTx. Approaches to mitigate the impact of CMV on posttransplant survival are needed.

摘要

背景

既往研究表明,巨细胞病毒(CMV)感染是心脏移植血管病变(CAV)发生的危险因素,且与心脏移植(HTx)后长期生存率降低相关。这项国际心肺移植学会移植登记研究的目的是比较不同CMV供体:受体血清学组合的移植后生存率。

方法

我们使用国际心肺移植学会胸科移植登记处,对2004年7月至2014年6月期间15885例已知CMV血清学状态的成年原发性心脏移植受者进行了一项回顾性队列研究。比较了4组患者的移植后生存率和发生CAV的风险:接受CMV阳性移植物(D+)的CMV血清学阴性受者(R-)、中度风险患者(D+R+和D-R+)以及低风险患者(D-R-)。

结果

各组之间的基线特征(供体/受体年龄、体重指数、受体血清肌酐、血型、供体死亡原因、受体诊断和缺血时间)大多平衡。10年随访期的Kaplan-Meier生存分析显示,与CMV低风险组相比,两个D+组的生存率均显著更差(D+R+:56.61%[95%置信区间,53.94-59.41] 对比 D-R-:63.09%[59.74-66.64],P<0.01;D+R-:57.69%[56.03-59.39] 对比 D-R-;P<0.001),而仅受体血清反应阳性与生存率降低无关(D-R+对比D-R-,P = 0.178)。与D-组相比,HTx后发生CAV的风险在D+组中未显著增加。

结论

在一个大型当代队列中,HTx时的CMV状态与CAV的发生无关。然而,供体CMV血清反应阳性与HTx后短期和长期生存率降低之间存在显著关联。需要采取措施减轻CMV对移植后生存的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验